



上海源叶生物科技有限公司  
Shanghai yuanye Bio-Technology Co., Ltd  
电话: 021-61312973 传真: 021-55068248  
网址: www.shyuanye.com  
邮箱: shyysw@sina.com

产品名称: ((+/-)-顺式-2-甲基螺[1,3-氧硫杂环戊烷-5,3'-奎宁环]盐酸半水合物  
产品别名: Cevimeline hydrochloride; 盐酸西维美林

生物活性:

Description	Cevimeline hydrochloride (AF102B hydrochloride) is a muscarinic M1 and M3 receptor agonist. Cevimeline hydrochloride acts a parasympathomimetic and muscarinic agonist used in the treatment of dry mouth associated with sjogren's syndrome.																									
IC <sub>50</sub> & Target	M3 receptor[1]																									
Solvent&Solubility	<p><b>In Vitro:</b></p> <p>H<sub>2</sub>O : ≥ 50 mg/mL (212.07 mM)</p> <p>* "≥" means soluble, but saturation unknown.</p> <table border="1"><thead><tr><th rowspan="2">Preparing Stock Solutions</th><th>Solvent / Mass</th><th>1 mg</th><th>5 mg</th><th>10 mg</th></tr><tr><th>Concentration</th><th></th><th></th><th></th></tr></thead><tbody><tr><td>1 mM</td><td>4.2414 mL</td><td>21.2071 mL</td><td>42.4142 mL</td></tr><tr><td>5 mM</td><td>0.8483 mL</td><td>4.2414 mL</td><td>8.4828 mL</td></tr><tr><td>10 mM</td><td>0.4241 mL</td><td>2.1207 mL</td><td>4.2414 mL</td></tr></tbody></table> <p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液。一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。</p> <p>储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。-80°C 储存时,请在 6 个月内使用, -20°C 储存时,请在 1 个月内使用。</p>					Preparing Stock Solutions	Solvent / Mass	1 mg	5 mg	10 mg	Concentration				1 mM	4.2414 mL	21.2071 mL	42.4142 mL	5 mM	0.8483 mL	4.2414 mL	8.4828 mL	10 mM	0.4241 mL	2.1207 mL	4.2414 mL
Preparing Stock Solutions	Solvent / Mass	1 mg	5 mg	10 mg																						
	Concentration																									
1 mM	4.2414 mL	21.2071 mL	42.4142 mL																							
5 mM	0.8483 mL	4.2414 mL	8.4828 mL																							
10 mM	0.4241 mL	2.1207 mL	4.2414 mL																							
References	<p>[1]. Witsell DL, et al. Effectiveness of cevimeline to improve oral health in patients with postradiation xerostomia. Head Neck. 2012 Aug;34(8):1136-42. doi: 10.1002/hed.21894. Epub 2012 Jan 9.</p> <p>[2]. Ono K, et al. Distinct effects of cevimeline and pilocarpine on salivary mechanisms, cardiovascular response and thirst sensation in rats. Arch Oral Biol. 2012 Apr;57(4):421-8. Epub 2011 Nov 17.</p> <p>[3]. Kondo Y, et al. Cevimeline-induced monophasic salivation from the mouse submandibular gland: decreased Na<sup>+</sup> content in saliva results from specific and early activation of Na<sup>+</sup>/H<sup>+</sup> exchange. J Pharmacol Exp Ther. 2011 Apr;337(1):267-74. Epub 2011 Jan 14.</p> <p>[4]. Voskoboinik B, et al. Cevimeline (Evoxac) overdose. J Med Toxicol. 2011 Mar;7(1):57-9.</p> <p>[5]. Tajiri S, et al. Dosage form design and in vitro/in vivo evaluation of cevimeline extended-release tablet formulations. Int J Pharm. 2010 Jan 4;383(1-2):99-105. Epub 2009 Sep 10.</p>																									